2022
DOI: 10.1002/ehf2.13963
|View full text |Cite
|
Sign up to set email alerts
|

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime

Abstract: Aims Duchenne muscular dystrophy (DMD) is an X‐linked recessive neuromuscular disorder, characterized by significant long‐term cardiac involvement. Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin‐converting enzyme inhibitors (ACEi) and beta‐blockers (BB) are first‐line treatments in DCM. It is unknown whether angiotensin receptor‐neprilysin inhibitor (ARNi) could provide greater benefits in this setting. Our aim is to assess whether ARNi use may prevent deterioration in ejection… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
references
References 16 publications
0
0
0
Order By: Relevance